SCEMBLIX 40 MG — DIN 02528339
ASCIMINIB (ASCIMINIB HYDROCHLORIDE) : 40 MG · NOVARTIS PHARMACEUTICALS CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is SCEMBLIX?
SCEMBLIX 40 MG contains ASCIMINIB (ASCIMINIB HYDROCHLORIDE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02528339, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Sep-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SCEMBLIX used for?
SCEMBLIX (asciminib tablets) is indicated for the treatment of: Adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who are newly diagnosed or who have previously received 1 or more tyrosine kinase inhibitors.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Asciminib cost around the world?
Asciminib is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 1 | 5 | AUD███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 2 | HUF███.██ |
| Iceland | max wholesale | 1 | 2 | ISK███.██ |
| Italy | ex-factory (classe H) | 2 | 2 | EUR███.██ |
| Romania | max producer price | 2 | 2 | RON███.██ |
| Saudi Arabia | public | 1 | 2 | SAR███.██ |
17 pack listings across 11 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Asciminib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Asciminib in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Asciminib — 2 DINs, of which 2 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVARTIS PHARMACEUTICALS CANADA INC | 2 | 2 | SCEMBLIX | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 40 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | SCEMBLIX 20 mg and 40 mg tablets are supplied in blister pack (10 blisters/card, 6 cards/carton). |
| Storage | Do not store above 25 °C. Store in the original package in order to protect from moisture. SCEMBLIX must be kept out of the reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Asciminib |
|---|---|
| ATC code | L01EA06 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02528339 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2528339 |
| Brand name | SCEMBLIX |
| Generic / active ingredient | ASCIMINIB (ASCIMINIB HYDROCHLORIDE) : 40 MG |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01EA06 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01EA |
| Current status | MARKETED |
| Status date | 01-Sep-2022 |
| Original market date | 2022-09-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Treatment with SCEMBLIX should be initiated by a physician experienced in the use of anticancer therapies. The pregnancy status of females of reproductive potential should be verified prior to starting treatment with SCEMBLIX. The recommended total daily dose of SCEMBLIX is 80 mg. SCEMBLIX can be taken orally either as 80 mg once daily at approximately the same time each day, or as 40 mg twice daily at approximately 12-hour intervals. Patients changing from 40 mg twice daily to 80 mg once daily should start taking SCEMBLIX once daily approximately 12 hours after the last twice-daily dose, and then continue at 80 mg once daily. Patients changing from 80 mg once daily to 40 mg twice daily should start taking SCEMBLIX twice daily approximately 24 hours after the last once-daily dose and then continue at 40 mg twice daily at approximately 12-hour intervals. SCEMBLIX should be taken orally without food. Food consumption should be avoided for at least 2 hours before and 1 hour after taking SCEMBLIX. SCEMBLIX tablets should be swallowed whole and should not be broken, crushed or chewed. If a SCEMBLIX dose is missed by more than approximately 12 hours (once-daily regimen), it should be skipped and the next dose should be taken as scheduled. If a SCEMBLIX dose is missed by more than approximately 6 hours (twice-daily regimen), it should be skipped and the next dose should be taken as scheduled.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
SCEMBLIX is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Cardiovascular toxicity (including ischemic cardiac and CNS conditions, arterial thrombotic and embolic conditions) and cardiac failure occurred in 37 (7%) and in 14 (3%) of 556 patients receiving SCEMBLIX, respectively. Grade 3 cardiovascular toxicity was reported in 12 (2%) patients, while grade 3 cardiac failure was observed in 8 (1%) patients. Grade 4 cardiovascular toxicity occurred in 3 (0.5%) patients, with fatalities occurring in 3 (0.5%) patients. Grade 4 cardiac failure was observed in 2 (0.4%) patients, with a fatality in 1 (0.2%) patient. Arrhythmia, including QTc prolongation, occurred in 36 of 556 (7%) patients receiving SCEMBLIX, with grade 3 or 4 arrhythmia reported in 11 (2%) and 2 (0.4%) patients, respectively. Electrocardiogram QTc prolongation occurred in 5 of 556 (0.9%) patients receiving SCEMBLIX, with grade 3 QTc prolongation reported in 2 out of 556 (0.4%) patients. Hypertension occurred in 88 of 556 (16%) patients receiving SCEMBLIX, with grade 3 and 4 reactions reported in 47 (9%) and 1 (0.2%) patients, respectively. Thrombocytopenia, neutropenia and anemia occurred in patients receiving SCEMBLIX. Severe (NCI CTCAE grade 3 or 4) thrombocytopenia and neutropenia were reported during treatment with SCEMBLIX. Pancreatitis occurred in 11 of 556 (2%) patients receiving SCEMBLIX, with grade 3 reactions occurring in 6 (1%) patients. Reactivation of hepatitis B virus (HBV) has occurred in patients who are chronic carriers of this virus following administration of other BCR::ABL1 tyrosine kinase inhibitors (TKIs). Patients should be tested for HBV infection before the start of treatment with SCEMBLIX. Hypersensitivity events occurred in 169 of 556 (30%) patients receiving SCEMBLIX, with zgrade 3 events reported in 8 (1%) patients.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SCEMBLIX | 20 MG | TABLET | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | 02528320 |
2 · Same class — other molecules in ATC L01EA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dasatinib | APO-DASATINIB · REDDY-DASATINIB · SPRYCEL · TARO-DASATINIB · +1 more | 28 | 28 | Yes |
| Imatinib | ACH-IMATINIB · APO-IMATINIB · GLEEVEC · IMATINIB · +8 more | 27 | 16 | Yes |
| Nilotinib | APO-NILOTINIB · REDDY-NILOTINIB · TASIGNA | 8 | 6 | Yes |
| Bosutinib | BOSULIF · REDDY-BOSUTINIB | 6 | 4 | Yes |
| Asciminib | SCEMBLIX | 2 | 2 | Yes |
| Ponatinib | ICLUSIG | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01EX | Avapritinib · Cabozantinib · Capivasertib · Capmatinib · Entrectinib · +17 more | 80 | 64 |
| L01EB | Afatinib · Dacomitinib · Erlotinib · Gefitinib · Lazertinib · +1 more | 40 | 23 |
| L01EF | Abemaciclib · Palbociclib · Ribociclib | 17 | 14 |
| L01ED | Alectinib · Brigatinib · Ceritinib · Crizotinib · Lorlatinib | 10 | 10 |
| L01EJ | Fedratinib · Momelotinib · Ruxolitinib | 8 | 8 |
| L01EE | Binimetinib · Cobimetinib · Selumetinib · Trametinib | 8 | 7 |
| L01EN | Erdafitinib · Infigratinib · Pemigatinib | 11 | 6 |
| L01EC | Dabrafenib · Encorafenib · Vemurafenib | 5 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is SCEMBLIX called?
Also recorded in Canada as: ASCIMINIB (GLOBAL), ASCIMINIB HYDROCHLORIDE (US), ASCIMINIB HYDROCHLORIDE (UK).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.